This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

The GSK DTaP vaccine portfolio provides consistent DTaP antigen content from

6 weeks through 6 years of age (prior to the seventh birthday)1-3

 

DU=D-antigen units; HBsAg=hepatitis B surface antigen; Lf=limits of flocculation.

Because the pertussis antigens contained in INFANRIX and KINRIX are the same as those in PEDIARIX, children who have received a 3-dose series with PEDIARIX should receive INFANRIX as their fourth dose of DTaP and either INFANRIX or KINRIX as their fifth dose of DTaP, according to the respective Prescribing Information for these vaccines.1

DTaP=diphtheria, tetanus, and acellular pertussis; IPV=inactivated poliovirus vaccine.

  • PEDIARIX as a primary series: Three doses of 0.5 mL each, by intramuscular injection, at 2, 4, and 6 months of age (at intervals of 6 to 8 weeks, preferably 8 weeks). The first dose may be given as early as 6 weeks of age. Three doses of PEDIARIX constitute a primary immunization course for diphtheria, tetanus, pertussis, and poliomyelitis and the complete vaccination course for hepatitis B. 1

    According to the Centers for Disease Control and Prevention (CDC), administration of a total of 4 doses of HepB vaccine is permitted when a combination vaccine containing HepB is administered after the birth dose. 4

    A 3-dose series of PEDIARIX may be administered to infants born of HBsAg-negative mothers and who received a dose of hepatitis B vaccine at or shortly after birth. However, data are limited regarding the safety of PEDIARIX in such infants 1
  • Booster immunization following PEDIARIX: Because the pertussis antigens contained in INFANRIX and KINRIX are the same as those in PEDIARIX, these children should receive INFANRIX as their fourth dose of DTaP and either INFANRIX or KINRIX as their fifth dose of DTaP, according to the respective Prescribing Information for these vaccines. KINRIX or another manufacturer's IPV may be used to complete the 4-dose IPV series according to the respective Prescribing Information 1

Sufficient data on the safety and effectiveness of interchanging PEDIARIX, INFANRIX, and KINRIX with DTaP-containing vaccines from different manufacturers are not available. 1-2

The GSK Portfolio of DTaP-containing Vaccines: Benefits That May Help Streamline the Vaccination Process by Reducing the Number of Steps

  • PEDIARIX, INFANRIX, and KINRIX are available in Tip-Lok® syringes

            - Single unit-dose prefilled for your conveniencea
            - Luer-Lok® adapter fits virtually any needle

  • The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
  • INFANRIX and KINRIX are also available in 0.5-mL single-dose vials. The vial stopper does not contain latex

a    Each syringe delivers the labeled dose.

References

  1. Prescribing Information for PEDIARIX.
  2. Prescribing Information for INFANRIX.
  3. Prescribing Information for KINRIX.
  4. Centers for Disease Control and Prevention. Recommended Immunization Schedules for Persons Aged 0 Through 18 Years--United States, 2016. http://www.cdc.gov/vaccines/schedules/
    downloads/child/0-18yrs-child-combined-schedule.pdf. Accessed November 12, 2019.
  5. American Medical Association. CPT (Current Procedural Terminology) 2016 Professional Edition. Chicago, IL: American Medical Association; 2015.

Indications for PEDIARIX, INFANRIX, and KINRIX

PEDIARIX is indicated for active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, and poliomyelitis. PEDIARIX is approved for use as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).

Please see full Prescribing Information for PEDIARIX.

INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years of age (prior to 7th birthday).

Please see full Prescribing Information for INFANRIX.

A single dose of KINRIX is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children aged 4 through 6 years (prior to 7th birthday) whose previous DTaP vaccine doses have been with INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) and/or PEDIARIX [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine] for the first 3 doses and INFANRIX for the fourth dose.

Please see full Prescribing Information for KINRIX.

Important Safety Information for PEDIARIX, INFANRIX, and KINRIX

  • Severe allergic reaction (eg, anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, pertussis-, hepatitis B-, or poliovirus-containing vaccine or to any component of PEDIARIX is a contraindication for PEDIARIX
  • Severe allergic reaction (eg, anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine or to any component of INFANRIX is a contraindication for INFANRIX
  • Severe allergic reaction (eg, anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, pertussis-, or poliovirus-containing vaccine or to any component of KINRIX, including neomycin and polymyxin B, is a contraindication for KINRIX
  • Additional contraindications for PEDIARIX, INFANRIX, and KINRIX are: encephalopathy within 7 days of administration of a previous pertussis-containing vaccine; progressive neurologic disorders
  • In clinical trials, PEDIARIX was associated with higher rates of fever relative to separately administered vaccines
  • The decision to give PEDIARIX, INFANRIX, or KINRIX should be based on potential benefits and risks if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, or if adverse events (ie, temperature ≥105°F, collapse or shock-like state, persistent, inconsolable crying lasting ≥3 hours, occurring within 48 hours after vaccination; seizures within 3 days after vaccination) have occurred after receipt of a pertussis-containing vaccine
  • The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
  • Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • For children at higher risk for seizures, an antipyretic may be administered at the time of vaccination with PEDIARIX, INFANRIX, or KINRIX
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination with PEDIARIX or INFANRIX should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination
  • In clinical trials of PEDIARIX and INFANRIX, common adverse reactions were injection-site reactions (pain, redness, and swelling), fever, drowsiness, irritability/fussiness, and loss of appetite. In clinical trials of KINRIX, common adverse reactions were injection-site reactions (pain, redness, increase in arm circumference, and swelling), drowsiness, fever, and loss of appetite
  • Vaccination with PEDIARIX, INFANRIX, or KINRIX may not result in protection in all vaccine recipients

All trademarks are the property of their respective owners.